P. Falciparum Malaria
5
0
0
4
Key Insights
Highlights
Success Rate
80% trial completion
Treatment Research
5 treatments under study, led by Dihydroartemisininpiperaquine
Research Leaders
7 sponsors active, led by University of Oxford
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
20.0%
1 terminated out of 5 trials
80.0%
-6.6% vs benchmark
40%
2 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (5)
Compare the Effectiveness Between Existing Treatment and New Treatment
Assessment of the Therapeutic Efficacy and Tolerability of the Artesunate/Amodiaquina Combination and Artemether/Lumefantrine Combination, Treatment of Uncomplicated P. Falciparum Malaria in the Department of Chocó (Colombia)
Evaluating the Efficacy of Artesunate-mefloquine and the Relative Roles of Resistance Genetic Markers
Assessing the Efficacy of Artemisinin Combination Therapies for Treatment of Uncomplicated Malaria Infection in Children
Re-exposure of EHMI-8 Human Volunteers to Live Malaria Sporozoites
Research Network
Common Treatments
- Dihydroartemisininpiperaquine2
- Mefloquineartesunate1
- Exposure To 5 P Falciparum Infected Mosquitoes1
- Artemeter Plus Lumefantrina Vs Artesunato Plus Amodiquina1
- Artemetherlumefantrine1
Active Sponsors
- University of Oxford2
- Radboud University Medical Center1
- Centers for Disease Control and Prevention1
- Nanyang Technological University1
- Sanofi Pasteur, a Sanofi Company1
Top Investigators
University of Oxford
Centers for Disease Control and Prevention
Centers for Disease Control and Prevention
Universidad Nacional de Colombia
Universidad Nacional de Colombia
Related Conditions
- P Falciparum Malaria Mixed Infection1